Compensatory point mutations in the human immunodeficiency virus type 1 Gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication
about
Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably?A new NMR solution structure of the SL1 HIV-1Lai loop-loop dimerCoordination of Genomic RNA Packaging with Viral Assembly in HIV-1Wrapping up the bad news: HIV assembly and releaseDelineation of the preferences and requirements of the human immunodeficiency virus type 1 dimerization initiation signal by using an in vivo cell-based selection approach.C-terminal domain modulates the nucleic acid chaperone activity of human T-cell leukemia virus type 1 nucleocapsid protein via an electrostatic mechanism.Leader sequences downstream of the primer binding site are important for efficient replication of simian immunodeficiency virus.Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site.Context-dependent phenotype of a human immunodeficiency virus type 1 nucleocapsid mutation.Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation.Mutations in matrix and SP1 repair the packaging specificity of a Human Immunodeficiency Virus Type 1 mutant by reducing the association of Gag with spliced viral RNAEffects of a single amino acid substitution within the p2 region of human immunodeficiency virus type 1 on packaging of spliced viral RNAFundamental differences between the nucleic acid chaperone activities of HIV-1 nucleocapsid protein and Gag or Gag-derived proteins: biological implicationsThe dimer initiation sequence stem-loop of human immunodeficiency virus type 1 is dispensable for viral replication in peripheral blood mononuclear cells.Clinical significance of human immunodeficiency virus type 1 replication fitness.PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of ageGenetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strainsImpact of human immunodeficiency virus type 1 RNA dimerization on viral infectivity and of stem-loop B on RNA dimerization and reverse transcription and dissociation of dimerization from packaging.Deletion mutagenesis downstream of the 5' long terminal repeat of human immunodeficiency virus type 1 is compensated for by point mutations in both the U5 region and gag gene.Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins.Hydrophobic amino acids in the human immunodeficiency virus type 1 p2 and nucleocapsid proteins can contribute to the rescue of deleted viral RNA packaging signals.Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome.Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.HIV-1 Pr55Gag binds genomic and spliced RNAs with different affinity and stoichiometry.
P2860
Q24805927-2B1B8F51-03ED-434F-9D73-F7319742BEF4Q25255880-80143C6C-0F47-49C2-990A-7BB06B6BE4BAQ26739673-7A1DC3B7-6515-4414-8794-4652139A115BQ26992150-34E7814D-7C77-4160-BC2F-6BE9D02056C2Q33561552-DE70837E-B6C9-40FD-A7DA-F7EC56B51B65Q33581258-887FDBF4-D330-44CF-A547-8E7E9B366B4BQ33604023-8B87F918-A379-4DC7-AC2D-BC6BC8F2F2B9Q33804495-9452F4F0-A49E-410D-9019-13D7344E878BQ33818125-EC733A0F-E08B-435A-B890-A898FDF8950DQ33844733-DDE16091-BDAB-4349-B1D6-BE8228543506Q33845445-10F2BE7D-5815-4DA2-9505-87DBC7BE214EQ34138829-5BB99191-CC40-4DDE-A7BB-BCB377D80A88Q34226913-F60FCBAA-BEEC-421A-B0E3-8DAB438E69D1Q34237075-63707D75-BAE2-4687-9FD8-18029543B160Q35155279-7B824A22-A682-4E45-A332-8FD3F29F8843Q36969857-228F260D-A0C8-488A-AB72-0752874F5E60Q37089562-D82EFBF1-D650-426E-A3DA-FD0A03530777Q37265589-5609A334-0578-4B0A-BCC1-5F92CD95086EQ39549272-E32EDE58-1758-4BF7-841E-23AF79C896B2Q39591516-BAE817AE-40E8-4FD8-8EE6-832122BB8ECAQ39591893-D2B5FB55-FE54-4E31-B061-B5AED3D1AF24Q39594983-9C82C5DC-468D-4E98-A679-02AE8F0E3904Q39606338-D6F266A7-D46E-47BB-83DE-8CA02C238115Q40112158-82680531-07D5-4FD3-9F20-0C6F8DF4065DQ40404514-742E5C1E-4ED7-4AB7-A52E-0C15EB61A3C2Q40476785-7DEF42A2-3EDA-4C91-841B-4F8937DA4386
P2860
Compensatory point mutations in the human immunodeficiency virus type 1 Gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Compensatory point mutations i ...... can restore viral replication
@en
Compensatory point mutations i ...... can restore viral replication.
@nl
type
label
Compensatory point mutations i ...... can restore viral replication
@en
Compensatory point mutations i ...... can restore viral replication.
@nl
prefLabel
Compensatory point mutations i ...... can restore viral replication
@en
Compensatory point mutations i ...... can restore viral replication.
@nl
P2093
P2860
P1433
P1476
Compensatory point mutations i ...... can restore viral replication
@en
P2093
P2860
P304
P407
P577
1998-08-01T00:00:00Z